Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study

Wong et al., The Lancet Infectious Diseases, doi:10.1016/S1473-3099(22)00507-2 (date from preprint)

May 2022

Source PDF All Studies Meta AnalysisMeta

PSM retrospective 40,776 patients in Hong Kong, showing lower mortality and lower combined mortality, ventilation, ICU, and oxygen therapy with paxlovid treatment.

Resistance. Variants may be resistant to paxlovid1-3. Use may promote the emergence of variants that weaken host immunity and potentially contribute to long COVID4.

Confounding by contraindication. Hoertel et al. find that over 50% of patients that died had a contraindication for the use of Paxlovid5. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.

Black box warning. The FDA notes that "severe, life-threatening, and/or fatal adverse reactions due to drug interactions have been reported in patients treated with paxlovid"6.

AKI. Kamo et al. show significantly increased risk of acute kidney injury.

Important missing comments or errors? Let us know.

Study covers paxlovid and molnupiravir.

risk of death, 66.0% lower, HR 0.34, p < 0.001, treatment 890, control 890, propensity score matching.

risk of mechanical ventilation, 3.0% lower, HR 0.97, p = 0.96, treatment 890, control 890, propensity score matching.

combined death/ventilation/ICU/oxygen, 43.0% lower, HR 0.57, p < 0.001, treatment 890, control 890, propensity score matching.

hospitalization time, 4.3% lower, relative time 0.96, p = 0.32, treatment 890, control 890, propensity score matching.

Ct<30, 27.5% lower, HR 0.72, p = 0.01, treatment 890, control 890, inverted to make HR<1 favor treatment, propensity score matching.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

1. Zhou et al., Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system, Science Advances, doi:10.1126/sciadv.add7197.science.org, doi.org.

2. Jochmans et al., The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir, mBio, doi:10.1128/mbio.02815-22.asm.org, doi.org.

3. Lopez et al., SARS-CoV-2 Resistance to Small Molecule Inhibitors, Current Clinical Microbiology Reports, doi:10.1007/s40588-024-00229-6.springer.com, doi.org.

4. Thomas et al., Nirmatrelvir-Resistant Mutations in SARS-CoV-2 Mpro Enhance Host Immune Evasion via Cleavage of NF-κB Essential Modulator, bioRxiv, doi:10.1101/2024.10.18.619137.biorxiv.org, doi.org.

5. Hoertel et al., Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease, JAMA Network Open, doi:10.1001/jamanetworkopen.2022.42140.jamanetwork.com, doi.org.

6. FDA, Fact sheet for healthcare providers: emergency use authorization for paxlovid, www.fda.gov/media/155050/download.fda.gov.

7. Kamo et al., Association of Antiviral Drugs for the Treatment of COVID-19 With Acute Renal Failure, In Vivo, doi:10.21873/invivo.13637.iiarjournals.org, doi.org.

Wong et al., 20 May 2022, retrospective, China, peer-reviewed, 6 authors, study period 26 February, 2022 - 26 April, 2022. Contact: carlosho@hku.hk, bcowling@hku.hk.

This Paper Paxlovid All

{ 'indexed': {'date-parts': [[2022, 8, 24]], 'date-time': '2022-08-24T23:12:45Z', 'timestamp': 1661382765673}, 'reference-count': 37, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2022, 8, 1]], 'date-time': '2022-08-01T00:00:00Z', 'timestamp': 1659312000000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.com', 'em-consulte.com', 'thelancet.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2022, 8]]}, 'DOI': '10.1016/s1473-3099(22)00507-2', 'type': 'journal-article', 'created': {'date-parts': [[2022, 8, 24]], 'date-time': '2022-08-24T22:34:53Z', 'timestamp': 1661380493000}, 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised ' "patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's " 'omicron BA.2 wave: a retrospective cohort study', 'prefix': '10.1016', 'author': [ {'given': 'Carlos K H', 'family': 'Wong', 'sequence': 'first', 'affiliation': []}, {'given': 'Ivan C H', 'family': 'Au', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kristy T K', 'family': 'Lau', 'sequence': 'additional', 'affiliation': []}, {'given': 'Eric H Y', 'family': 'Lau', 'sequence': 'additional', 'affiliation': []}, {'given': 'Benjamin J', 'family': 'Cowling', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gabriel M', 'family': 'Leung', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/S1473-3099(22)00507-2_bib5', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fphar.2022.816429', 'article-title': 'Effectiveness of antiviral therapy in highly-transmissible variants of ' 'SARS-CoV-2: a modeling and simulation study', 'volume': '13', 'author': 'Schöning', 'year': '2022', 'journal-title': 'Front Pharmacol'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib6', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.dsx.2022.102396', 'article-title': 'An updated practical guideline on use of molnupiravir and comparison ' 'with agents having emergency use authorization for treatment of ' 'COVID-19', 'volume': '16', 'author': 'Singh', 'year': '2022', 'journal-title': 'Diabetes Metab Syndr'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib7', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fimmu.2022.855496', 'article-title': 'Molnupiravir and its antiviral activity against COVID-19', 'volume': '13', 'author': 'Tian', 'year': '2022', 'journal-title': 'Front Immunol'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib8', 'doi-asserted-by': 'crossref', 'first-page': 'o443', 'DOI': '10.1136/bmj.o443', 'article-title': "Molnupiravir's authorisation was premature", 'volume': '376', 'author': 'Brophy', 'year': '2022', 'journal-title': 'BMJ'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib9', 'article-title': 'COVID-19: FDA expert panel recommends authorising molnupiravir but also ' 'voices concerns', 'volume': '375', 'author': 'Dyer', 'year': '2021', 'journal-title': 'BMJ'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib10', 'doi-asserted-by': 'crossref', 'first-page': 'o977', 'DOI': '10.1136/bmj.o977', 'article-title': 'Imbalance in baseline characteristics in molnupiravir trials', 'volume': '377', 'author': 'Hama', 'year': '2022', 'journal-title': 'BMJ'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib11', 'doi-asserted-by': 'crossref', 'first-page': 'e231', 'DOI': '10.1016/S1473-3099(22)00119-0', 'article-title': 'Availability of oral antivirals against SARS-CoV-2 infection and the ' 'requirement for an ethical prescribing approach', 'volume': '22', 'author': 'Dal-Ré', 'year': '2022', 'journal-title': 'Lancet Infect Dis'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib12', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.eclinm.2021.100743', 'article-title': 'Clinical outcomes of different therapeutic options for COVID-19 in two ' 'Chinese case cohorts: a propensity-score analysis', 'volume': '32', 'author': 'Wong', 'year': '2021', 'journal-title': 'EClinicalMedicine'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib13', 'doi-asserted-by': 'crossref', 'article-title': 'Vaccine effectiveness of one, two, and three doses of BNT162b2 and ' 'CoronaVac against COVID-19 in Hong Kong: a population-based ' 'observational study', 'author': 'McMenamin', 'year': '2022', 'journal-title': 'Lancet Infect Dis', 'DOI': '10.1016/S1473-3099(22)00345-0'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib17', 'doi-asserted-by': 'crossref', 'first-page': '41', 'DOI': '10.1001/jamainternmed.2020.6252', 'article-title': 'Association between early treatment with tocilizumab and mortality ' 'among critically ill patients with COVID-19', 'volume': '181', 'author': 'Gupta', 'year': '2021', 'journal-title': 'JAMA Intern Med'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib18', 'doi-asserted-by': 'crossref', 'first-page': '2', 'DOI': '10.1186/s13054-020-03422-3', 'article-title': 'Early corticosteroids are associated with lower mortality in critically ' 'ill patients with COVID-19: a cohort study', 'volume': '25', 'author': 'Monedero', 'year': '2021', 'journal-title': 'Crit Care'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib19', 'doi-asserted-by': 'crossref', 'first-page': '1452', 'DOI': '10.1093/aje/kwab028', 'article-title': 'Biases in evaluating the safety and effectiveness of drugs for the ' 'treatment of COVID-19: designing real-world evidence studies', 'volume': '190', 'author': 'Renoux', 'year': '2021', 'journal-title': 'Am J Epidemiol'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib20', 'doi-asserted-by': 'crossref', 'first-page': '1450', 'DOI': '10.1093/cid/ciab631', 'article-title': 'Clinical improvement, outcomes, antiviral activity, and costs ' 'associated with early treatment with remdesivir for patients with ' 'coronavirus disease 2019 (COVID-19)', 'volume': '74', 'author': 'Wong', 'year': '2022', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib22', 'doi-asserted-by': 'crossref', 'first-page': '377', 'DOI': '10.1002/sim.4067', 'article-title': 'Multiple imputation using chained equations: issues and guidance for ' 'practice', 'volume': '30', 'author': 'White', 'year': '2011', 'journal-title': 'Stat Med'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib23', 'doi-asserted-by': 'crossref', 'first-page': '3', 'DOI': '10.1177/0962280217713032', 'article-title': 'Propensity score analysis with partially observed covariates: how ' 'should multiple imputation be used?', 'volume': '28', 'author': 'Leyrat', 'year': '2019', 'journal-title': 'Stat Methods Med Res'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib24', 'doi-asserted-by': 'crossref', 'first-page': '171', 'DOI': '10.1002/bimj.200810488', 'article-title': 'Some methods of propensity-score matching had superior performance to ' 'others: results of an empirical investigation and Monte Carlo ' 'simulations', 'volume': '51', 'author': 'Austin', 'year': '2009', 'journal-title': 'Biom J'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib25', 'doi-asserted-by': 'crossref', 'article-title': 'Molnupiravir and nirmatrelvir–ritonavir: oral COVID antiviral drugs', 'author': 'Saravolatz', 'year': '2022', 'journal-title': 'Clin Infect Dis', 'DOI': '10.1093/cid/ciac180'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib27', 'doi-asserted-by': 'crossref', 'first-page': '1397', 'DOI': '10.1056/NEJMoa2118542', 'article-title': 'Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19', 'volume': '386', 'author': 'Hammond', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib28', 'doi-asserted-by': 'crossref', 'first-page': '509', 'DOI': '10.1056/NEJMoa2116044', 'article-title': 'Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients', 'volume': '386', 'author': 'Jayk Bernal', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib29', 'article-title': 'Effectiveness of paxlovid in reducing severe COVID-19 and mortality in ' 'high risk patients', 'author': 'Najjar-Debbiny', 'year': '2022', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib30', 'article-title': 'Oral nirmatrelvir and severe COVID-19 outcomes during the omicron surge', 'author': 'Arbel', 'year': '2022', 'journal-title': 'Research Square'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib31', 'doi-asserted-by': 'crossref', 'DOI': '10.1056/EVIDoa2100044', 'article-title': 'Randomized trial of molnupiravir or placebo in patients hospitalized ' 'with COVID-19', 'volume': '1', 'author': 'Arribas', 'year': '2022', 'journal-title': 'NEJM Evidence'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib32', 'doi-asserted-by': 'crossref', 'article-title': 'Effect of molnupiravir on biomarkers, respiratory interventions, and ' 'medical services in COVID-19: a randomized, placebo-controlled trial', 'author': 'Johnson', 'year': '2022', 'journal-title': 'Ann Intern Med', 'DOI': '10.7326/M22-0729'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib33', 'doi-asserted-by': 'crossref', 'first-page': '319', 'DOI': '10.1038/s41422-022-00619-9', 'article-title': 'Reduced interferon antagonism but similar drug sensitivity in omicron ' 'variant compared to delta variant of SARS-CoV-2 isolates', 'volume': '32', 'author': 'Bojkova', 'year': '2022', 'journal-title': 'Cell Res'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib34', 'doi-asserted-by': 'crossref', 'first-page': '322', 'DOI': '10.1038/s41422-022-00618-w', 'article-title': 'SARS-CoV-2 omicron variant is highly sensitive to molnupiravir, ' 'nirmatrelvir, and the combination', 'volume': '32', 'author': 'Li', 'year': '2022', 'journal-title': 'Cell Res'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib35', 'doi-asserted-by': 'crossref', 'first-page': '995', 'DOI': '10.1056/NEJMc2119407', 'article-title': 'Efficacy of antibodies and antiviral drugs against COVID-19 omicron ' 'variant', 'volume': '386', 'author': 'Takashita', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib36', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.antiviral.2022.105252', 'article-title': 'Remdesivir, molnupiravir and nirmatrelvir remain active against ' 'SARS-CoV-2 omicron and other variants of concern', 'volume': '198', 'author': 'Vangeel', 'year': '2022', 'journal-title': 'Antiviral Res'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib37', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.bmcl.2022.128629', 'article-title': 'Main protease mutants of SARS-CoV-2 variants remain susceptible to ' 'nirmatrelvir', 'volume': '62', 'author': 'Ullrich', 'year': '2022', 'journal-title': 'Bioorg Med Chem Lett'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib38', 'doi-asserted-by': 'crossref', 'first-page': '1475', 'DOI': '10.1056/NEJMc2201933', 'article-title': 'Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant ' 'BA.2', 'volume': '386', 'author': 'Takashita', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib39', 'series-title': 'Hetero announces interim clinical results from phase III clinical trials ' 'of molnupiravir conducted in India', 'year': '2021'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib40', 'doi-asserted-by': 'crossref', 'DOI': '10.1126/scitranslmed.abl7430', 'article-title': 'A phase 2a clinical trial of molnupiravir in patients with COVID-19 ' 'shows accelerated SARS-CoV-2 RNA clearance and elimination of ' 'infectious virus', 'volume': '14', 'author': 'Fischer', 'year': '2022', 'journal-title': 'Sci Transl Med'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib42', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fphar.2022.939573', 'article-title': 'Antiviral efficacy and safety of molnupiravir against omicron variant ' 'infection: a randomized controlled clinical trial', 'volume': '13', 'author': 'Zou', 'year': '2022', 'journal-title': 'Front Pharmacol'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib43', 'first-page': '41', 'article-title': 'Oral antivirals for the prevention and treatment of SARS-CoV-2 ' 'infection', 'volume': '24', 'author': 'Soriano', 'year': '2022', 'journal-title': 'AIDS Rev'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib46', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.dsx.2021.102329', 'article-title': 'Molnupiravir in COVID-19: a systematic review of literature', 'volume': '15', 'author': 'Singh', 'year': '2021', 'journal-title': 'Diabetes Metab Syndr'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib47', 'doi-asserted-by': 'crossref', 'first-page': '37', 'DOI': '10.1002/em.22471', 'article-title': 'Human genetic risk of treatment with antiviral nucleoside analog drugs ' 'that induce lethal mutagenesis: the special case of molnupiravir', 'volume': '63', 'author': 'Waters', 'year': '2022', 'journal-title': 'Environ Mol Mutagen'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib48', 'doi-asserted-by': 'crossref', 'first-page': '415', 'DOI': '10.1093/infdis/jiab247', 'article-title': 'β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis ' 'but is also mutagenic to mammalian cells', 'volume': '224', 'author': 'Zhou', 'year': '2021', 'journal-title': 'J Infect Dis'}, { 'key': '10.1016/S1473-3099(22)00507-2_bib49', 'doi-asserted-by': 'crossref', 'DOI': '10.3390/ijms23073507', 'article-title': 'Potential resistance of SARS-CoV-2 main protease (Mpro) against ' 'protease inhibitors: lessons learned from HIV-1 protease', 'volume': '23', 'author': 'Mótyán', 'year': '2022', 'journal-title': 'Int J Mol Sci'}], 'container-title': 'The Lancet Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1473309922005072?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1473309922005072?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 8, 24]], 'date-time': '2022-08-24T22:35:19Z', 'timestamp': 1661380519000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1473309922005072'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 8]]}, 'references-count': 37, 'alternative-id': ['S1473309922005072'], 'URL': 'http://dx.doi.org/10.1016/S1473-3099(22)00507-2', 'relation': {}, 'ISSN': ['1473-3099'], 'subject': ['Infectious Diseases'], 'container-title-short': 'The Lancet Infectious Diseases', 'published': {'date-parts': [[2022, 8]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in ' 'hospitalised patients with COVID-19 without supplemental oxygen requirement on ' "admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study", 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'The Lancet Infectious Diseases', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/S1473-3099(22)00507-2', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, { 'value': 'https://doi.org/10.1016/S1473-3099(22)00522-9', 'name': 'associatedlink', 'label': 'CrossRef DOI link to the associated document'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2022 Elsevier Ltd. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}]}

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0